Comparison of the diagnostic value of histopathological examinations of miscarriage products after pharmacological induction of miscarriage and curettage by Sliwa, Jakub et al.
331
ORIGINAL PAPER /  OBSTE TRICS
Ginekologia Polska
2019, vol. 90, no. 6, 331–335
Copyright © 2019 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2019.0061
Corresponding author:
Anna Kryza-Ottou
Medical University of Wroclaw, Departament of Obstetrics and Gynecology, 213 Borowska St, 50-556 Wroclaw, Poland
e-mail: ania.kryza@interia.pl
Comparison of the diagnostic value of 
histopathological examinations of miscarriage 
products after pharmacological induction of 
miscarriage and curettage
Jakub Sliwa1, Anna Kryza-Ottou1, Anna Rosner-Tenerowicz1,  
Maciej Kaczorowski2, Mariusz Zimmer1, Zygmunt Domagala3
1Medical University of Wroclaw, Departament of Obstetrics and Gynecology, Wroclaw, Poland 
2Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland 
3Department of Anatomy, Morphology and Human Embryology, Wroclaw Medical University, Wroclaw, Poland
ABSTRACT
Objectives: For early miscarriage (pregnancy loss ≤ 12 weeks of gestation), two types of therapeutic treatment are offered 
(pharmacotherapy and curettage of the uterine cavity) depending on the presence and severity of clinical symptoms as 
well as patient choice. Our study aimed to assess the diagnostic value of the results of histopathological examinations of 
miscarriage products in relation to the administered treatments.
Material and methods: 850 medical records from patients diagnosed with missed miscarriage or empty gestational sac 
were analyzed retrospectively. Patients underwent surgical treatment or pharmacotherapy. Inefficacy of pharmacotherapy 
resulted in subsequent curettage. The results of histopathology were evaluated for their diagnostic value and classified: 
subgroup 1 — high value specimen (the studied specimen included fetal tissues, and villi), and subgroup 2 — no-diagnosis 
(the studied specimen included maternal tissues, autolyzed tissues, blood clots). Data were compared with chi-squared 
test. Differences was considered significant at p < 0.05.
Results: 1128 histopathological test results were analyzed; 569 (50.4%) were obtained during pharmacotherapy and 
559 (49.6%) after curettage; out of the latter 497 after the initial pharmacotherapy and 62 after surgery. In the pharmaco-
therapy group, high value specimens comprised 231 cases (40.59%) while no diagnosis was obtained in 338 cases (59.4%). 
Considering specimens obtained in the course curettage, high value specimens were found in 364 cases (65.1%) while 
results that did not allow a diagnosis to be made were found in 195 cases (34.9%). 
Conclusions: Tissue specimens of high diagnostic value are obtained significantly more often during surgical treatment 
of miscarriage than during pharmacotherapy. 
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INTRODUCTION
Early miscarriage is a term used to describe the loss 
of pregnancy within the first 12 weeks of gestation. 
This diagnosis concerns 10–15% of all pregnancies [1, 2] and 
is made based on additional tests such as serial determina-
tions of chorionic gonadotrophin concentration and imaging 
examinations — ultrasonography [1–3]. Depending on the 
clinical presentation and results of ultrasonography, miscar-
riages can be divided into complete spontaneous miscarriage, 
and incomplete miscarriage, when the width of the echo of 
residual tissues in the uterine cavity exceeds 10 mm on ultra-
sonography and is accompanied by the presence of clinical 
symptoms such as vaginal bleeding and abdominal pain [4]. 
The other type of miscarriage is defined as retained products 
of conception (RPOC) and refers to the state when the ges-
tational sac contains the embryo with crown-rump length 
(CRL) of > 7 mm but embryonic cardiac activity is invisible [3]. 
Empty gestational sac is diagnosed when the gestational 
sac with a diameter of > 25 mm and without an embryo is 
visible in the uterine cavity on ultrasonography [3].
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When miscarriage is diagnosed, therapeutic decisions 
are made depending on the type of miscarriage, the pres-
ence and severity of clinical symptoms, as well as patient 
choice; the patient is informed about possible therapeutic 
options together with the advantages and disadvantages of 
each option [5–8]. Historically, a diagnosis of miscarriage re-
sulted in immediate curettage of the uterine cavity in order 
to avoid complications associated with gestational tissues 
remaining in the uterine cavity such as hemorrhage, local 
or generalized infection, and proliferation of trophoblastic 
tissue leading to gestational trophoblastic disease [5, 6]. 
In the literature, two methods of treatment are described. 
The first method is the classic approach based on curettage 
of the uterine cavity. It allows for the removal of gestational 
tissues from the uterine cavity and the direct collection of 
specimens for histopathological examination. The second 
one is based on pharmacological treatment with cytostat-
ics, analogues of prostaglandins and/or selective estrogen 
receptor modulators [6, 7, 9–12]. 
The legitimacy of routine histopathological assessment 
of uterine products of miscarriage is currently under debate 
[13–23]. Some authors opt for routine histopathological ex-
amination of gestational tissues as a necessary supplement 
to the miscarriage therapy because it enables treatment 
maintenance in the case of a proliferative pathology of 
the trophoblast [13–19]. An additional argument for histo-
pathological examination is the possibility to obtain guid-
ance on the necessity of further tests (e.g., genetic tests) 
and help make the final diagnosis in cases with pregnancy 
of unknown location [15–18]. Other group of researchers 
claims that the routine histopathological examination has 
no justification, and recommended only in particular cases 
when ultrasound examination suggests features of tropho-
blast pathology or in patients with habitual miscarriages as 
well as when the results of the histopathologic examina-
tion are required for the diagnosis [7, 21–23]. According 
to NICE guidelines from 2014 regarding management of 
ectopic pregnancy and miscarriage, there is no evidence 
for the necessity of further monitoring and additional tests 
following miscarriage [24]. The Royal College of Patholo-
gists recommends histopathological examination in late 
miscarriages, but the decision to conduct such an examina-
tion is left to the discretion of guidelines of local obstetric 
and gynecological associations [25]. Similar to previous 
institution, NHS England Standard Contract recommends 
a histopathological examination in cases of unexplained 
pregnancy loss after 12 weeks of gestation [26]. 
Aim of the Study
The aim of the study was to assess the diagnostic value 
of the histopathological examination results of miscarriage 
products in missed miscarriage and empty gestational sac in 
relation to the administered treatment — pharmacological 
induction of miscarriage vs. curettage of the uterine cavity. 
MATERIALS AND METHODS
The retrospective analysis comprised 850 records from 
patients with a clinical and ultrasound diagnosis of missed 
miscarriage or empty gestational sac hospitalized in the 
2nd Department of Gynecology and Obstetrics of the 
Medical University in Wroclaw, Poland, between 2014 and 
2017. Patients with first-trimester pregnancies at admis-
sion were included. Cases with spontaneous inevitable 
miscarriage and well as incomplete and complete miscar-
riage. The study group was homogenous in terms of race 
and nationality. Pharmacological and/or surgical treatment 
was conducted taking into account patient preference. 
Pharmacotherapy included administration of 800 µg of 
misoprostol a day (two doses of 400 µg for 2 days). On the 
3rd day a transvaginal ultrasound was performed. The treat-
ment was considered unsuccessful if residual tissues in the 
uterine cavity of > 10 mm were visible on ultrasonography; 
then patients were subjected to curettage of the uterine 
cavity. All patients were hospitalized until the treatment 
was successful.
All tissue specimens were obtained by qualified medical 
staff — midwives. They were first assessed macroscopi-
cally for the presence of tissues and next, after fixation of 
the specimens in a 10% solution of formalin, they were 
packed accordingly and sent to the Department of Patho-
morphology and Oncological Cytology at Wroclaw Medical 
University, Poland, for histopathology. For histopathological 
evaluation, formalin-fixed and paraffin-embedded tissues 
were used. Paraffin blocks were cut into 4 µm-thick sections 
subsequently mounted on sialinized glass slides, which were 
then subjected to automated staining with hematoxylin and 
eosin in Sakura Tissue-Tek Prisma & Film Slide Stainer and 
Coverslipper (Sakura Finetek Europe B.V., Alphen aan den 
Rijn, The Netherlands). Evaluation of slides was performed 
by means of light microscopy (Olympus BX51; Olympus 
America, Inc., Melville, NY). Results included information 
about the presence of fetal tissues, villi, maternal tissues 
— decidua, as well as other structures such as blood clots 
and autolyzed tissues. 
Data from medical records such as parity, gestational 
age, and diagnosis, as well as the type of applied treatment 
and the way the material for histopathology was obtained, 
were statistically analyzed. Patients who did not achieve 
successful evacuation of tissues from the uterine cavity in 
the course of pharmacological treatment were subjected 
to the combination treatment — the first specimen was 
sampled during pharmacological treatment and the second 
during curettage of the uterine cavity. The combination 
treatment was administered to 497 initially treated with 
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pharmacotherapy. In those cases, 2 specimens were collect-
ed for histopathology and both included into analysis. From 
850 patients, ultimately 1128 results of histopathological 
tests were obtained. The results of histopathology were 
evaluated for their diagnostic value and classified into the 
following subgroups: subgroup 1 — high value specimen 
(the studied specimen included fetal tissues, and villi), and 
subgroup 2 — no-diagnosis (the studied specimen included 
maternal tissues - decidua, autolyzed tissues, blood clots but 
no fetal tissues and villi).
Data were collected in an Excel spreadsheet and then 
statistically analyzed using R Project for statistical comput-
ing v 3.4.1. The data were presented as means (standard 
deviation) or median (range) and numbers (percentages) 
depending on their type and distribution. Two groups 
of categorical variables were compared with Pearson’s 
chi-squared test. Differences were considered statistically 
significant at p < 0.05
RESULTS
In the studied group of 850 women with the mean age of 
32.7 years (range from 17 to 44 years of age), median parity 
was 1.94 (from 1 to 7). Mean gestational age at diagnosis was 
8.8 ± 1.9 weeks of gestation and ranged from 6 to 12 ges-
tational weeks. Overall, 18.9% of studied patients reported 
at least 1 miscarriage in the history (range from 1 to 5). 
In the study group, 746 (86%) of women were diagnosed 
with missed miscarriage, while 110 (13%) had empty ges-
tational sac (Tab. 1). 
Pharmacotherapy was given to 788 (92.7%) pa-
tients. Of these, 291 (34.2%) did not require further treat-
ment, 497 (58.5%) women were treated with combined 
therapy with pharmacotherapy followed by curettage of 
the uterine cavity due to the lack of efficacy of pharma-
cotherapy applied. Surgical treatment was performed as 
the initial method of choice in 62 (7.3%) patients. Types of 
administered treatment are presented in Table 2.
In total, 1128 tissues specimens were collected from 
850 patients. All 1128 specimens were divided into 2 groups: 
group A — specimens obtained in the course of pharmacologi-
cal induction of miscarriage (n = 569) and group B — speci-
mens obtained in the course of curettage of the uterine cavity 
(n = 559; 497 results after the initial pharmacotherapy and 
62 results treated with surgery as the method of choice) (Tab. 3).
Taking into account histopathological results, in the 
pharmacotherapy group (group A), high value specimens 
(subgroup 1) comprised 231 cases (40.59%) while no di-
agnosis (subgroup 2) was obtained in 338 cases (59.4%). 
Considering specimens obtained in the course curettage 
(group B), high value specimens (subgroup 1) were found in 
364 (65.1%) results while results that did not allow a diagno-
sis to be made (subgroup 2) were found in 195 cases (34.9%). 
The difference was statistically significant (p < 0.05) based 
on Chi square test. Results of histopathological examination 
are summarized in Table 4.
A total of 4 cases (0.5%) were diagnosed with molar 
pregnancy (2 complete molar pregnancies and 2 partial 
molar pregnancies). Those patients were initially subjected 
to pharmacotherapy, which was unsuccessful, and then to 
curettage of the uterine cavity. It is important to note that 
in those cases, specimens for histopathology were obtained 
solely after curettage because, after pharmacotherapy, pa-
tients failed to deliver specimens, or the histopathology 
gave a non-diagnostic result. As many as 497 women (63.1%) 
required additional curettage after the initial pharmaco-
therapy due to its lack of effectiveness — defined as the 
presence of the echo of tissues of > 10 mm in the uterine 
cavity. In the present study, the efficacy of pharmacotherapy 
was 36.9%. Efficacy of pharmacological treatment is pre-
sented in Table 5.
Table 1. Distribution of patient by diagnosis
Type of miscarriage Number of cases Percentage
Missed abortion 740 87.1%
Blight ovum 110 12.9%
Total 850 100%
Table 2. Distribution of patients by the type of treatment
Type of treatment Number of procedures Percentage
Pharmacotherapy only 291 34.2%
Surgery only 62 7.3%
Combined treatment 
(pharmacotherapy + surgery)
497 58.5%
Total 850 100%
Table 3. Distribution of histopathological results by the type of 
treatment (mode of collecting specimens)
Type of treatment
Number of histopathological 
results
Percentage
Pharmacotherapy 569 50.4%
Surgical treatment 559 49.6%
Total 1128 100%
Table 4. Value of histopathology results
Value Group A Group B
High value specimen 231 (40.6%) 364 (65.1%)
No diagnosis 338 (59.4%) 195 (34.9%)
Total 569 (100%) 559 (100%)
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DISCUSSION
In the last few decades, an increase in the frequency 
of pharmacological management of spontaneous miscar-
riage, including missed miscarriage and empty gestational 
sac, has been observed in many medical centers [4–6, 12]. 
The advantages of this option are obvious, as this method 
is non-invasive and well-accepted by patients, does not 
require anesthesia, and results in a lower percentage of 
short- and long-term complications in comparison to curet-
tage [5, 6, 27, 28]. However, it is associated with longer hos-
pitalization; increased and prolonged blood loss; increased 
demand for emergency intervention due to complications of 
pharmacotherapy; and most of all with lower efficacy [5, 6, 9, 
27–29]. In the present study, the pharmacotherapy success 
rate was 36.9%; the efficacy reported by other authors differs 
and ranges from 47% to 91.5% [9, 10, 13, 30, 31]. Our analysis 
revealed that the majority of patients subjected to pharma-
cotherapy, i.e., 63.1% of them, required subsequent curet-
tage of the uterine cavity for evacuation of biological tissues 
or debris from the uterus. Sotiriadis et al. [30] reported that 
pharmacological treatment was less effective than curettage 
of the uterine cavity (66% vs 100%, respectively); however, 
they observed higher efficacy of pharmacotherapy than is 
presented in our study. The present study revealed that in 
case of pharmacological treatment, we were able to collect 
high value diagnostic specimens in 40.6% of specimens 
analyzed. In the study performed by Petersen et al. [27], 
only 22.8% of cases treated with pharmacotherapy were 
able to deliver specimens for histopathology; however, in 
this study specimens were not assessed for their quality and 
diagnostic value. Converse results are presented by Heath 
et al. [21] who reports that 99.5% of patients treated with 
pharmacotherapy delivered specimens for histopathology 
that allowed a diagnosis to be made. It is worth noting that 
this study employed different procedure based on different 
dosing schedule and combined therapy with misoprostol 
i mifepristone. In the literature, there is a lack of data evaluat-
ing a diagnostic value of specimens collected in the course 
of miscarriage treatment depending to the method of treat-
ment applied. In the present study, the diagnostic value of 
the material obtained in the course of miscarriage treatment 
was presented depending on the method of treatment. 
A statistically significant difference in diagnostic value was 
shown between cases treated with pharmacotherapy and 
curettage of the uterine cavity.
In the literature, there is an ongoing debate on the le-
gitimacy of the routine histopathological examination of 
tissues obtained after miscarriage [13, 15–18, 20–23]. One of 
the aims of the histopathological examination of gestational 
tissues is the detection of trophoblast pathology such as 
gestational trophoblastic disease, molar pregnancy, and cho-
riocarcinoma. Based on data from the literature, the incidence 
of trophoblastic disease is estimated to range from 0.57 to 
1.1 per 1,000 pregnancies [30, 32] The local incidence of ges-
tational trophoblastic disease may be the factor that is worth 
considering when making a decision to conduct a routine his-
topathologic examination of obtained tissues. This can also 
affect the rate of high diagnostic value of specimens, e.g. the 
incidence of hydatidiform mole is rated at 1 in 80 pregnancies 
in Asia, whereas 1 in 500–1500 pregnancies in the countries 
of Western Europe and 1 in 452–1098 pregnancies in Saudi 
Arabia. The incidence of this complication decreases over 
time with improvement in health care [7]. Biscaro et al. [33] 
revealed that the frequency of detection of molar tissues was 
2.2% in specimens obtained during curettage of the uterine 
cavity. In the present study, a lower frequency of 0.5% was 
observed and no case of choriocarcinoma was found when 
analyzing specimens obtained in the course of curettage.
Other information from histopathological examinations 
can play a role in the diagnostic process, such as the detec-
tion of chromosomal aberrations in fetal tissues and other 
facts helpful for determining the location of pregnancies of 
unknown location. Those should be considered as further 
arguments for conducting routine histopathological examina-
tions [13, 15–18, 20]. Heath et al. claim that the frequency of 
disorders diagnosed by histopathological examination is low 
and does not support routine tests. It may be considered as 
a diagnostic extension solely in questionable cases. The fre-
quency of trophoblast disorders reported by Heath et al. [21] 
was as low as 0.1%. Similarly, Alsibiani at al. [7] claims that his-
topathological examination should be performed in selected 
cases. However, in light of the serious consequences rooted in 
the delay in diagnosis or misdiagnosis of women who did not 
have such an examination — and thus leading to a delay in the 
administration of proper therapy — many authors claim that 
the histopathological examination still constitutes an obliga-
tory element which supplements the diagnosis and treatment 
of early pregnancy failure [13, 15, 19, 28]. We agree with this 
view due to medical and legal consequences resulting from 
undetected trophoblast diseases or delayed diagnosis — his-
topathological assessment should be performed in every case 
of miscarriage regardless of the incidence of those diseases as 
well as results of imaging examinations and clinical symptom. 
CONCLUSIONS
Tissue specimens of high diagnostic value are obtained 
significantly more often during surgical treatment of mis-
Table 5. Efficacy of pharmacological treatment
Value Number of procedures Percentage
Incomplete 497 63.1%
Complete 291 36.9%
Total 788 100%
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carriage than during pharmacotherapy. Histopathological 
results of no diagnosis are more often associated with the 
specimens obtained in the course of pharmacological pro-
cedure in comparison to invasive procedure. We recommend 
conducting histopathological examination in every case of 
miscarriage regardless of the mode of therapy applied due 
to medical and legal consequences resulting from unde-
tected trophoblast diseases or delayed diagnosis despite 
their rare incidence. When trophoblast pathology is sus-
pected, obtaining tissue specimens for histopathology is 
recommended, which can be ensured by invasive treatment. 
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